A Phase 3 Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

About this Study

The purpose of the study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma who are MRD-positive after undergoing ASCT.

Sponsor Protocol ID:C1071007
IRB Number:2023-111
Actively Enrolling
Phase 3
November 20, 2023
Eligibility Criteria
Both Male and Female
Categories Click category to view its trials.
Participating Locations
Cancer Center and Research Institute - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Jennifer Barnes
Phone Number: 601-815-4540
Email: jbarnes@umc.edu
Principal Investigator:Stephanie Elkins
How to participate in our Clinical Trials